0001140361-21-008343.txt : 20210312
0001140361-21-008343.hdr.sgml : 20210312
20210312163601
ACCESSION NUMBER: 0001140361-21-008343
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210308
FILED AS OF DATE: 20210312
DATE AS OF CHANGE: 20210312
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BALTHROP PATRICK J
CENTRAL INDEX KEY: 0001284839
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36200
FILM NUMBER: 21737973
MAIL ADDRESS:
STREET 1: 243 LEEDS COURT
CITY: LAKE BLUFF
STATE: IL
ZIP: 60044
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oxford Immunotec Global PLC
CENTRAL INDEX KEY: 0001586049
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 000000000
STATE OF INCORPORATION: X0
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 94C INNOVATION DRIVE
STREET 2: MILTON PARK
CITY: ABINGDON
STATE: X0
ZIP: OX14 4RZ
BUSINESS PHONE: 44 01235 442780
MAIL ADDRESS:
STREET 1: 94C INNOVATION DRIVE
STREET 2: MILTON PARK
CITY: ABINGDON
STATE: X0
ZIP: OX14 4RZ
4
1
form4.xml
FORM 4
X0306
4
2021-03-08
true
0001586049
Oxford Immunotec Global PLC
OXFD
0001284839
BALTHROP PATRICK J
C/O OXFORD IMMUNOTEC GLOBAL PLC
94C INNOVATION DRIVE
ABINGDON, OXFORDSHIRE
X0
OX14 4RZ
UNITED KINGDOM
true
Ordinary Shares
2021-03-08
4
D
0
8081
22
D
0
D
Stock Option (Right to Buy)
11.62
2021-03-08
4
D
0
3728
10.38
D
2026-01-29
Ordinary Shares
3728
0
D
Stock Option (Right to Buy)
11.62
2021-03-08
4
D
0
14914
10.38
D
2026-01-29
Ordinary Shares
14914
0
D
Stock Option (Right to Buy)
8.65
2021-03-08
4
D
0
7457
13.35
D
2026-06-28
Ordinary Shares
7457
0
D
Stock Option (Right to Buy)
14.46
2021-03-08
4
D
0
7457
7.54
D
2027-06-06
Ordinary Shares
7457
0
D
Stock Option (Right to Buy)
14.49
2021-03-08
4
D
0
7457
7.51
D
2028-06-19
Ordinary Shares
7457
0
D
Stock Option (Right to Buy)
14.44
2021-03-08
4
D
0
7457
7.56
D
2029-06-18
Ordinary Shares
7457
0
D
Stock Option (Right to Buy)
12.96
2021-03-08
4
D
0
9494
9.04
D
2030-06-24
Ordinary Shares
9494
0
D
Disposed pursuant to the acquisition by PerkinElmer (UK) Holdings Limited of the entire issued share capital of Oxford Immunotec Global PLC on March 8, 2021 by means of a scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme").
In connection with the Scheme, all stock options were cancelled in exchange for a payment equal to $22.00 with respect to each ordinary share subject to the option award, less the applicable exercise price.
Represents the payment per ordinary share received in exchange for the cancellation of each option of $22.00, less the applicable exercise price.
/s/ Matthew T E McLaughlin, as Attorney-in-Fact for Patrick J. Balthrop, Sr.
2021-03-12